In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME)
暂无分享,去创建一个
S. Larson | M. McDevitt | D. Veach | D. Thorek | D. Pankov | R. O'reilly | D. Ulmert | Kjell Sjöström | T. Kalidindi | Rui Gardner | Sang-gyu Lee | L. Sjöström
[1] J. Marshall,et al. A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors , 2011, Journal of immunotherapy.
[2] M. Zahurak,et al. Characterization of chronic myeloid leukemia stem cells , 2011, American journal of hematology.
[3] S. Larson,et al. Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution. , 2015, Nuclear medicine and biology.
[4] Niklas Thurfjell. p63 – from expression to function : studies of normal oral mucosa and squamous cell carcinoma of the head and neck , 2007 .
[5] L. O’Driscoll,et al. Prevalence and prognostic and predictive relevance of PRAME in breast cancer , 2008, Breast Cancer Research and Treatment.
[6] R. Sanyal,et al. Quantification of CD20 mRNA and protein levels in chronic lymphocytic leukemia suggests a post-transcriptional defect. , 2010, Leukemia research.
[7] M. Kizaki,et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia , 2001, British journal of haematology.
[8] R. Bernards,et al. The Human Tumor Antigen PRAME Is a Dominant Repressor of Retinoic Acid Receptor Signaling , 2005, Cell.
[9] V. Thorsson,et al. Integrated Genomic and Proteomic Analyses of Gene Expression in Mammalian Cells*S , 2004, Molecular & Cellular Proteomics.
[10] A. Simpson,et al. PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. , 2006, Leukemia research.
[11] F. Berthold,et al. The Tumor-Associated Antigen PRAME Is Universally Expressed in High-Stage Neuroblastoma and Associated with Poor Outcome , 2004, Clinical Cancer Research.
[12] E. Ballestar,et al. Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment. , 2012, Leukemia research.
[13] S. Loening,et al. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. , 2002, European urology.
[14] D. Abou,et al. In vivo biodistribution and accumulation of 89Zr in mice. , 2011, Nuclear medicine and biology.
[15] Millard,et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells , 1998, British journal of haematology.
[16] P. Coulie,et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. , 1997, Immunity.
[17] R. Lempicki,et al. Comparison of mRNA and Protein Measures of Cytokines following Vaccination with Human Papillomavirus-16 L1 Virus-like Particles , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[18] F. Prósper,et al. Epigenetic regulation of PRAME gene in chronic myeloid leukemia. , 2007, Leukemia research.
[19] Franco H Falcone,et al. PRAME Is a Golgi-Targeted Protein That Associates with the Elongin BC Complex and Is Upregulated by Interferon-Gamma and Bacterial PAMPs , 2013, PloS one.
[20] A. Dalgleish,et al. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2′-Deoxycytidine , 2011, Cancer Immunology, Immunotherapy.
[21] J. Pollack,et al. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. , 2006, Blood.
[22] Y. Matsuzawa,et al. Bisecting N-acetylglucosamine on K562 cells suppresses natural killer cytotoxicity and promotes spleen colonization. , 1996, Cancer research.
[23] J. Utikal,et al. Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study , 2016, ESMO Open.
[24] M. Maio,et al. Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2′-deoxycytidine , 2004, Cancer Research.
[25] T. De Pas,et al. Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.